How big is the urokinase market today, and what are its future growth expectations?
The urokinase market size has grown strongly in recent years. It will grow from $1.7 $ billion in 2024 to $1.81 $ billion in 2025 at a compound annual growth rate (CAGR) of 6.0%. The growth in the historic period can be attributed to the increasing incidence of stroke and heart attacks, growth in clinical research, regulatory approvals for critical indications, development of initial formulations, and growing healthcare infrastructure.
The urokinase market size is expected to see strong growth in the next few years. It will grow to $2.26 $ billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to a growing focus on personalized medicine, increasing prevalence of pulmonary embolism, growing investment in cardiovascular and stroke research, increase in diagnostic and imaging techniques, rise in geriatric population, and rising incidence of obesity. Major trends in the forecast period include advancements in personalized medicine, technological innovations in drug delivery systems, integration of AI and digital health tools, advancements in digital health platforms, and development in clinical research.
Get Your Free Sample of The Global Urokinase Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19745&type=smp
What have been the primary factors driving the urokinase market’s growth?
The growing burden of cardiovascular diseases is expected to propel the growth of the urokinase market going forward. Cardiovascular diseases (CVDs) refer to a range of disorders affecting the heart and blood vessels, including conditions such as heart attacks, strokes, and hypertension. The rising burden of cardiovascular diseases is due to factors such as higher obesity rates caused by a lack of physical activity, unhealthy eating habits, and an aging population. Urokinase contributes to alleviating the increasing impact of cardiovascular diseases by breaking down blood clots that block blood flow, helping prevent heart attacks and strokes, restoring proper circulation, and mitigating further cardiovascular damage. For instance, in August 2022, according to a report published by the American College of Cardiology, a US-based non-profit medical association, in the United States, it is projected that all four major cardiovascular risk factors will increase from 2025 to 2060. Diabetes is expected to see the largest percentage rise, with a 39.3% increase to 55 million individuals. Additionally, significant increases in cardiovascular disease rates are anticipated for stroke (33.8% to 15 million) and heart failure (33.4% to 13 million), with ischemic heart disease (30.7% to 29 million) and heart attack (16.9% to 16 million) following closely behind. Therefore, the growing burden of cardiovascular diseases is driving the growth of the urokinase market.
What are the key segments within the urokinase market?
The urokinasemarket covered in this report is segmented –
1) By Type: Urokinase Powder, Urokinase Solution
2) By Manufacturing Process: Biotechnological Methods, Traditional Extraction
3) By Indication: Catheter Clearance, Coronary Artery Thrombosis, Deep Vein Thrombosis, Pulmonary Embolism
4) By Distribution channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By Application: Hospital, Clinics, Other Applications
Subsegments:
1) By Urokinase Powder: Pharmaceutical-Grade Urokinase Powder, Research-Grade Urokinase Powder, Recombinant Urokinase Powder
2) By Urokinase Solution: Injectable Urokinase Solution, Infusion Urokinase Solution, Pre-mixed Urokinase Solution
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/urokinase-global-market-report
Which key players are shaping the urokinase market?
Major companies operating in the urokinase market are Thermo Fisher Scientific Inc., Mochida Pharmaceutical Co. Ltd., Bharat Serums and Vaccines Limited, Taj Pharmaceuticals Ltd., TTK Health Care Limited, Agrata Biotech Limited, Cerbios-Pharma SA, Microbix Biosystems Inc., Midas Pharma GmbH, ImaRx Therapeutics, Health Biotech Limited, Salvavidas Pharmaceutical Pvt. Ltd., BBT Biotech GmbH, Syner-Med (Pharmaceutical Products) Ltd., Echelon Biosciences Inc., Kraeber & Co GmbH, Samarth Life Science Pvt. Ltd., WUHAN HANWEISHI PHARMCHEM CO. LTD., Aetos Pharma, MITS CRITICAL CARE
How will emerging trends drive the urokinase market throughout the forecast period?
Major companies operating in the urokinase market are reintroducing and commercializing pharmaceutical products for new indications to enhance treatment efficacy, market competitiveness, and patient accessibility. Reintroduction and commercialization of a pharmaceutical product for new indications involve the process of bringing a previously available or discontinued drug back to the market for new disease treatment and implementing strategies to make it available and successful through marketing, distribution, and sales efforts. For instance, in May 2023, MBX Biosciences, a US-based biopharmaceutical company, partnered with Sequel Pharma LLC, a US-based pharmaceutical company, to reintroduce and commercialize kinlytic urokinase. It aims to enhance its presence in the catheter clearance market and improve treatment outcomes for patients. This collaboration highlights the trend of leveraging strategic partnerships to effectively revive and promote pharmaceutical products, ensuring they meet current market needs and regulatory standards.
How do regional factors impact the urokinase market, and which region is the largest contributor?
North America was the largest region in the urokinase market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the urokinase market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Urokinase Market Report 2025 Offer?
The urokinase market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Urokinase is a therapeutic enzyme that acts as a thrombolytic agent to dissolve blood clots. It works by activating plasminogen into plasmin, which then degrades fibrin, the primary protein in blood clots. It is used in clinical settings to treat conditions such as acute myocardial infarction and other blood clotting-related diseases by restoring blood flow and reducing the risk of severe complications from clot formation.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19745
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
